<!DOCTYPE html>
<html lang="tr">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro | UzunYaÅŸa</title>
    <meta name="description" content="Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? TÃ¼m klinik veriler ve TÃ¼rkiye'deki eriÅŸim bilgileri.">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
    <style>
        :root { --primary: #195157; --accent: #E8963E; --text: #1f2937; --text-gray: #6b7280; --bg: #FAF9F7; }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Inter', sans-serif; color: var(--text); line-height: 1.8; background: var(--bg); }
        .header { position: fixed; top: 0; left: 0; right: 0; z-index: 1000; background: rgba(255,255,255,0.97); backdrop-filter: blur(10px); border-bottom: 1px solid #e5e7eb; }
        .header-inner { max-width: 1200px; margin: 0 auto; padding: 0.75rem 2rem; display: flex; align-items: center; justify-content: space-between; }
        .logo-img { height: 50px; }
        .back-link { color: var(--primary); text-decoration: none; font-weight: 500; }
        article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
        .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; }
        .post-category { display: inline-block; background: #EC4899; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
        .reading-time { color: var(--text-gray); font-size: 0.9rem; }
        h1 { font-family: 'Playfair Display', serif; font-size: 2.5rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; color: var(--text); }
        .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; line-height: 1.6; }
        .featured-image { width: 100%; height: 300px; background: linear-gradient(135deg, rgba(236,72,153,0.8), rgba(219,39,119,0.8)), url("https://images.unsplash.com/photo-1631549916768-4119b2e5f926?w=800&q=80") center/cover; border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; }
        .featured-image span { font-size: 4rem; }
        .toc { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.5rem; margin-bottom: 2rem; }
        .toc h3 { font-size: 1rem; font-weight: 600; margin-bottom: 1rem; color: var(--primary); }
        .toc ul { list-style: none; }
        .toc li { margin-bottom: 0.5rem; }
        .toc a { color: var(--text-gray); text-decoration: none; font-size: 0.9rem; }
        .toc a:hover { color: var(--primary); }
        .content p { margin-bottom: 1.5rem; font-size: 1.05rem; }
        .content h2 { font-size: 1.6rem; font-weight: 700; margin: 3rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
        .content h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text); }
        .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
        .content li { margin-bottom: 0.5rem; font-size: 1.02rem; }
        .content strong { color: var(--text); }
        .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .success-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
        .quote-box { background: #faf5ff; border-left: 4px solid #8b5cf6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; font-style: italic; }
        .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 1rem; margin: 2rem 0; }
        .stat-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; text-align: center; }
        .stat-card .number { font-size: 1.75rem; font-weight: 800; color: var(--primary); }
        .stat-card .label { font-size: 0.8rem; color: var(--text-gray); margin-top: 0.25rem; }
        table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.95rem; }
        th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
        th { background: #f8fafc; font-weight: 600; color: var(--primary); }
        .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
        .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
        .author-box { display: flex; align-items: center; gap: 1rem; padding: 1.5rem; background: white; border-radius: 12px; border: 1px solid #e5e7eb; margin: 2rem 0; }
        .author-avatar { width: 60px; height: 60px; background: var(--primary); border-radius: 50%; display: flex; align-items: center; justify-content: center; color: white; font-weight: 700; }
        .author-info h4 { font-weight: 600; margin-bottom: 0.25rem; }
        .author-info p { font-size: 0.85rem; color: var(--text-gray); }
        footer { background: var(--text); color: white; padding: 2rem; text-align: center; }
        @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } .stat-grid { grid-template-columns: repeat(2, 1fr); } }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
            <a href="../blog.html" class="back-link">â† Blog</a>
        </div>
    </header>

    <article>
        <div class="post-meta-top">
            <span class="post-category">ğŸ’Š GLP-1 Ä°laÃ§larÄ±</span>
            <span class="reading-time">â±ï¸ 18 dk okuma â€¢ Åubat 2026</span>
        </div>
        
        <h1>GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro</h1>
        <p class="subtitle">Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? Yan etkileri neler? BÄ±rakÄ±nca ne olur? TÃ¼m klinik veriler, gerÃ§ekÃ§i beklentiler ve TÃ¼rkiye'deki eriÅŸim bilgileri.</p>

        <div class="featured-image"></div>

        <div class="toc">
            <h3>ğŸ“‹ Ä°Ã§indekiler</h3>
            <ul>
                <li><a href="#nedir">GLP-1 Ä°laÃ§larÄ± Nedir?</a></li>
                <li><a href="#nasil">NasÄ±l Ã‡alÄ±ÅŸÄ±rlar?</a></li>
                <li><a href="#ilaclar">Piyasadaki Ä°laÃ§lar</a></li>
                <li><a href="#kilo">Kilo KaybÄ± Verileri</a></li>
                <li><a href="#faydalar">DiÄŸer SaÄŸlÄ±k FaydalarÄ±</a></li>
                <li><a href="#yan-etkiler">Yan Etkiler</a></li>
                <li><a href="#birakinca">BÄ±rakÄ±nca Ne Olur?</a></li>
                <li><a href="#turkiye">TÃ¼rkiye'de EriÅŸim</a></li>
            </ul>
        </div>

        <div class="content">
            <h2 id="nedir">GLP-1 Ä°laÃ§larÄ± Nedir?</h2>
            <p>GLP-1 reseptÃ¶r agonistleri, bir neslin en Ã¶nemli ilaÃ§ sÄ±nÄ±fÄ± haline geldi. BaÅŸlangÄ±Ã§ta tip 2 diyabet tedavisi iÃ§in geliÅŸtirilen bu ilaÃ§lar, obezite tedavisinde devrim yarattÄ±.</p>
            
            <p>"GLP-1" kÄ±saltmasÄ±, <strong>Glucagon-Like Peptide-1</strong> anlamÄ±na gelir â€” baÄŸÄ±rsaklarÄ±mÄ±zÄ±n yemek yediÄŸimizde doÄŸal olarak salgÄ±ladÄ±ÄŸÄ± bir hormon.</p>

            <div class="stat-grid">
                <div class="stat-card"><div class="number">25M+</div><div class="label">DÃ¼nya genelinde hasta</div></div>
                <div class="stat-card"><div class="number">%15-22</div><div class="label">Ortalama kilo kaybÄ±</div></div>
                <div class="stat-card"><div class="number">%20</div><div class="label">Kalp hastalÄ±ÄŸÄ± risk azalmasÄ±</div></div>
            </div>

            <h2 id="nasil">NasÄ±l Ã‡alÄ±ÅŸÄ±rlar?</h2>
            
            <h3>1. Beyin Ãœzerindeki Etki</h3>
            <p>Ä°laÃ§lar, beyindeki tokluk merkezini (hipotalamus) uyararak aÃ§lÄ±k hissini dramatik ÅŸekilde azaltÄ±r. Hastalar genellikle "yemek dÃ¼ÅŸÃ¼nmÃ¼yorum artÄ±k" ÅŸeklinde tanÄ±mlar.</p>

            <h3>2. Mide Ãœzerindeki Etki</h3>
            <p>Midenin boÅŸalma hÄ±zÄ±nÄ± yavaÅŸlatÄ±r. Yemekten sonra daha uzun sÃ¼re tok hissedersiniz.</p>

            <h3>3. Pankreas Ãœzerindeki Etki</h3>
            <p>Kan ÅŸekeri yÃ¼kseldiÄŸinde insÃ¼lin salÄ±nÄ±mÄ±nÄ± artÄ±rÄ±r, dÃ¼ÅŸÃ¼k olduÄŸunda artÄ±rmaz. Bu "akÄ±llÄ±" mekanizma hipoglisemi riskini minimuma indirir.</p>

            <h2 id="ilaclar">Piyasadaki GLP-1 Ä°laÃ§larÄ±</h2>

            <h3>Semaglutid Ailesi (Novo Nordisk)</h3>
            <table>
                <tr><th>Ä°laÃ§</th><th>Endikasyon</th><th>Doz</th><th>Uygulama</th></tr>
                <tr><td><strong>Ozempic</strong></td><td>Tip 2 diyabet</td><td>0.25-2 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
                <tr><td><strong>Wegovy</strong></td><td>Obezite</td><td>2.4 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
                <tr><td><strong>Rybelsus</strong></td><td>Tip 2 diyabet</td><td>3-14 mg/gÃ¼n</td><td>GÃ¼nlÃ¼k oral tablet</td></tr>
            </table>

            <h3>Tirzepatid Ailesi (Eli Lilly)</h3>
            <table>
                <tr><th>Ä°laÃ§</th><th>Endikasyon</th><th>Doz</th><th>Uygulama</th></tr>
                <tr><td><strong>Mounjaro</strong></td><td>Tip 2 diyabet</td><td>5-15 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
                <tr><td><strong>Zepbound</strong></td><td>Obezite</td><td>5-15 mg/hafta</td><td>HaftalÄ±k enjeksiyon</td></tr>
            </table>

            <div class="info-box">
                <strong>ğŸ’¡ Ã–nemli fark:</strong> Tirzepatid, "Ã§ift agonist" olarak hem GLP-1 hem de GIP reseptÃ¶rlerini aktive eder. Bu nedenle semaglutidden daha yÃ¼ksek kilo kaybÄ± saÄŸlar.
            </div>

            <h2 id="kilo">Kilo KaybÄ±: Klinik Ã‡alÄ±ÅŸma Verileri</h2>

            <h3>Semaglutid (Wegovy): STEP Ã‡alÄ±ÅŸmalarÄ±</h3>
            <p><strong>STEP 1</strong> (1.961 katÄ±lÄ±mcÄ±, 68 hafta):</p>
            <ul>
                <li>Semaglutid grubu: <strong>%14.9</strong> kilo kaybÄ±</li>
                <li>â‰¥%10 kilo kaybÄ±: <strong>%69.1</strong> hastada</li>
                <li>â‰¥%15 kilo kaybÄ±: <strong>%50.5</strong> hastada</li>
            </ul>

            <h3>Tirzepatid (Zepbound): SURMOUNT Ã‡alÄ±ÅŸmalarÄ±</h3>
            <p><strong>SURMOUNT-1</strong> (2.539 katÄ±lÄ±mcÄ±, 72 hafta):</p>
            <ul>
                <li>15 mg doz: <strong>%20.9</strong> kilo kaybÄ±</li>
                <li><strong>%57</strong> hastalar â‰¥%20 kilo kaybetti</li>
                <li><strong>%36</strong> hastalar â‰¥%25 kilo kaybetti</li>
            </ul>

            <div class="success-box">
                <strong>Kafa Kafaya KarÅŸÄ±laÅŸtÄ±rma (SURMOUNT-5):</strong><br>
                Tirzepatid: <strong>%20.2</strong> kilo kaybÄ±<br>
                Semaglutid: %13.7 kilo kaybÄ±<br>
                Fark: 6.5 puan tirzepatid lehine
            </div>

            <h2 id="faydalar">Kilo KaybÄ±nÄ±n Ã–tesinde: SaÄŸlÄ±k FaydalarÄ±</h2>

            <h3>Kalp-Damar SaÄŸlÄ±ÄŸÄ± (SELECT Ã‡alÄ±ÅŸmasÄ±)</h3>
            <ul>
                <li>MajÃ¶r kalp olaylarÄ±nÄ± <strong>%20 azalttÄ±</strong></li>
                <li>TÃ¼m nedenlerden Ã¶lÃ¼mÃ¼ <strong>%19 azalttÄ±</strong></li>
            </ul>

            <h3>BÃ¶brek KorumasÄ± (FLOW Ã‡alÄ±ÅŸmasÄ±)</h3>
            <ul>
                <li>MajÃ¶r bÃ¶brek olaylarÄ±nda <strong>%24 azalma</strong></li>
                <li>Ã‡alÄ±ÅŸma etkinlik nedeniyle erken durduruldu</li>
            </ul>

            <h3>KaraciÄŸer YaÄŸlanmasÄ± (ESSENCE)</h3>
            <ul>
                <li><strong>%37</strong> hastada MASH (yaÄŸlÄ± karaciÄŸer) Ã§Ã¶zÃ¼mÃ¼</li>
            </ul>

            <h2 id="yan-etkiler">Yan Etkiler ve Riskler</h2>

            <h3>En YaygÄ±n: Gastrointestinal</h3>
            <table>
                <tr><th>Yan Etki</th><th>Semaglutid</th><th>Plasebo</th></tr>
                <tr><td>BulantÄ±</td><td><strong>%43.9</strong></td><td>%16.1</td></tr>
                <tr><td>Ä°shal</td><td><strong>%29.7</strong></td><td>%15.9</td></tr>
                <tr><td>Kusma</td><td><strong>%24.5</strong></td><td>%6.3</td></tr>
                <tr><td>KabÄ±zlÄ±k</td><td><strong>%24.2</strong></td><td>%10.1</td></tr>
            </table>

            <div class="info-box">
                <strong>ğŸ’¡ Ã–nemli:</strong> Bu yan etkilerin %99.5'i ciddi deÄŸildi ve %98.1'i hafif-orta ÅŸiddetteydi. Sadece %4.3 hasta tedaviyi bÄ±raktÄ±.
            </div>

            <h3>Kas KaybÄ±</h3>
            <p>Kaybedilen kilonun %39-45'i yaÄŸsÄ±z kÃ¼tle. <strong>Ã–nlem:</strong></p>
            <ul>
                <li>Haftada 3-5 gÃ¼n direnÃ§ egzersizi</li>
                <li>GÃ¼nde 1.6-2.3 g/kg protein</li>
            </ul>

            <h2 id="birakinca">Kritik Soru: BÄ±rakÄ±nca Ne Olur?</h2>

            <div class="warning-box">
                <strong>âš ï¸ Ã–nemli UyarÄ±:</strong> Ä°laÃ§ bÄ±rakÄ±ldÄ±ÄŸÄ±nda kilo geri geliyor. STEP 1 uzantÄ±sÄ±nda, bÄ±rakÄ±ldÄ±ktan 1 yÄ±l sonra kaybedilen kilonun <strong>%67'si</strong> (yaklaÅŸÄ±k 2/3) geri alÄ±ndÄ±.
            </div>

            <p><strong>Geri AlÄ±mÄ± Azaltma Stratejileri:</strong></p>
            <ul>
                <li>YapÄ±landÄ±rÄ±lmÄ±ÅŸ egzersiz programÄ±</li>
                <li>YÃ¼ksek protein diyeti</li>
                <li>Kademeli doz azaltma</li>
                <li>Oral alternatiflere geÃ§iÅŸ</li>
            </ul>

            <div class="quote-box">
                <strong>ğŸ’¬ Biliyor Muydunuz?</strong><br>
                GLP-1 ilaÃ§larÄ±, hipertansiyon ilaÃ§larÄ± gibi dÃ¼ÅŸÃ¼nÃ¼lmeli. Tansiyon ilacÄ± bÄ±rakÄ±ldÄ±ÄŸÄ±nda tansiyon nasÄ±l yÃ¼kselirse, GLP-1 bÄ±rakÄ±ldÄ±ÄŸÄ±nda kilo da geri gelir. Bu, ilacÄ±n "baÅŸarÄ±sÄ±zlÄ±ÄŸÄ±" deÄŸil, kronik bir hastalÄ±ÄŸÄ±n doÄŸasÄ±.
            </div>

            <h2 id="turkiye">TÃ¼rkiye'de EriÅŸim ve Maliyet</h2>

            <table>
                <tr><th>Ä°laÃ§</th><th>TÃ¼rkiye Durumu</th><th>Tahmini AylÄ±k Maliyet</th></tr>
                <tr><td>Ozempic</td><td>ReÃ§eteli, SGK sÄ±nÄ±rlÄ±</td><td>3.500-5.000 TL</td></tr>
                <tr><td>Wegovy</td><td>HenÃ¼z resmi lansman yok</td><td>-</td></tr>
                <tr><td>Mounjaro</td><td>TÃ¼rkiye'de yok</td><td>-</td></tr>
            </table>

            <p><strong>2026-2027 Beklentisi:</strong> Semaglutid jenerikleri ile maliyet %50-70 azalabilir.</p>

            <h2>SonuÃ§: Sizin Ä°Ã§in DoÄŸru mu?</h2>

            <p><strong>GLP-1 ilaÃ§larÄ± uygun olabilir:</strong></p>
            <ul>
                <li>BMI â‰¥30 veya BMI â‰¥27 + komorbidite</li>
                <li>Diyet ve egzersizle baÅŸarÄ±sÄ±z olanlar</li>
                <li>Uzun vadeli tedaviye hazÄ±r olanlar</li>
            </ul>

            <p><strong>Uygun olmayabilir:</strong></p>
            <ul>
                <li>HÄ±zlÄ± Ã§Ã¶zÃ¼m arayanlar</li>
                <li>Uzun vadeli ilaÃ§ kullanÄ±mÄ± istemeyenler</li>
                <li>Maliyet engeliyle karÅŸÄ±laÅŸanlar</li>
            </ul>

            <div class="cta-box">
                <h3>Size uygun tedavi seÃ§eneÄŸini Ã¶ÄŸrenin</h3>
                <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in testimizi tamamlayÄ±n</p>
                <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
            </div>

            <div class="author-box">
                <div class="author-avatar">UY</div>
                <div class="author-info">
                    <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
                    <p>TÄ±bbi Ä°nceleme: Gastroenteroloji ve Endokrinoloji UzmanlarÄ± DanÄ±ÅŸma Kurulu</p>
                </div>
            </div>
        </div>
    </article>

    <footer><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
</body>
</html>
